Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies.
Julio RosenstockBertrand CariouJohanna EliassonGuillaume FrappinMargit S KaltoftEduard MontanyaFilip K Krag KnopPublished in: Diabetes, obesity & metabolism (2023)
Oral semaglutide 7 and 14 mg resulted in greater time spent with HbA1c less than 7.0%, and a greater likelihood of achieving and maintaining HbA1c less than 7.0% versus oral comparators.
Keyphrases